|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sustained release octreotide may have a role in the treatment of malignant bowel obstruction显示文摘 | Massacesi C Galeazzi G | | 0，，07： | 1 |
| 2 | Uridine diph- osphate glucuronosyl transferase 1A1 promoter polymor- phism predicts the risk of gastrointestinal toxicity and fa- tigue induced by irinotecan-based chemotherapy 显示文摘 | Massacesi C Terrazzino S Marcucci F | 2006 | Can- cer2006，106，5： | 1 |
| 3 | Uridine djphosphate glucuronosyJtransferase 1 A1 promoterpolymorphism predicts the riskof gastrointestinal toxicity andfatigue induced by irinotecan-basedchemotherapy显示文摘 | Massacesi C Terrazzino S Marcucci F | 2006 | Cancer2006，106，5： | 1 |
| 4 | Uridine diphosphate glucuronosyl transferase 1A 1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy 显示文摘 | Massacesi C Terrazzino S Marcucci F | 2006 | Cancer2006，106，5： | 1 |
| 5 | Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase Ⅱ study 显示文摘 | Santini D Massacesi C D'Angelillo RM | 2004 | Med Oncol2004，21，1： | 1 |
| 6 | Randomized,muhicenter, phase Ⅱ study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer 显示文摘 | Mazzanti P Massacesi C Rocchi MB | 2003 | Lung Cancer2003，41，1： | 1 |
| 7 | Randomized , multicenter, Phase Ⅱ study of gemcitabine plus cisplalin versus gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer显示文摘 | Massacesi C Rocchi ML | 2003 | Lung Cancer2003，41，1： | 1 |
| 8 | Randomized,multicenter,phase Ⅱ study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer显示文摘 | Mazzanti P Massacesi C Rocchi MB | 2003 | Lung Cancer2003，41，1： | 1 |
| 9 | Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy 显示文摘 | MASSACESI C TERRAZZINO S MARCUCCI F | 2006 | Cancer2006，106，5： | 1 |
| 10 | Randomized, multicenter, phase Ⅱ study of gemcitabine plus cisplatin versus gemcitabine plus carboplatln in patients with advanced non-small cell lung cancer显示文摘 | Mazzanti P Massacesi C Rocchi MBL | | Lung Cancer0，41，1： | 1 |
| 11 | Uridine diphosphateglucuronosy transferase 1 A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy显示文摘 | Massacesi C Terrazzino S Marcucci F | 2006 | Cancer2006，106，5： | 1 |
| 12 | Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer显示文摘 | Massacesi C Marcucci F Boccetti T | 2005 | J Exp Clin Cancer Res2005，24，1： | 1 |
| 13 | Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinote- can--based chemotherapy显示文摘 | Massacesi C Terrazzino S Marcucci F | 2006 | Cancer2006，106，5： | 1 |
| 14 | Reltitrexed plus weekly oxaliplatin as firstline chemotherapy in metastatic colorectal cancer: a muhicenter non - randonized phase H study 显示文摘 | Santinl D Massacesi C D'Angelillo RM | 2004 | Med Oncol2004，21，： | 1 |
| 15 | Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colonrectal cancer:a multicenter non-randomized phase II study显示文摘 | Santini D Massacesi C D'Angelillo RM et a1 | 2004 | Med Oncol2004，21，1： | 1 |
| 16 | Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy显示文摘 | Massacesi C Terrazzino S Marcucci F | 2006 | Cancer2006，106，5： | 1 |
| 17 | Uridine diphosphate glucuronosyl transferase 1 A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy显示文摘 | Massacesi C Terrazzino S Mareucci F | 2006 | Cancer2006，106，5： | 1 |
| 18 | Randomized, multi-center,Phase U study of gemcitabine plus cisplalin versus gemcitabine plus carboplatin in patients with advanced non-small-cemung cancer显示文摘 | Mazzanti P Massacesi C Rocchi ML | 2003 | Lung Cancer2003，41，1： | 1 |
| 19 | Randomized, multicenter, phase Ⅱ study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer显示文摘 | Mazzanti P Massacesi C Rocchi MB | 2003 | Lung Cancer2003，41，1： | 1 |
| 20 | Randomized,multieenter,phase II study of gemeitabine plus eisplatin versus gemeitabine plus Calboplatin in patients with advanced non-small-cel lung cancer显示文摘 | Mazzanti P Massacesi C Rocehi MB | 2003 | Lung cancer2003，41，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员